#USA #Pittsburgh #Wound Care #MolecuLight #Hayfin

MolecuLight Secures $27.5 Million from Hayfin: A New Era in Wound Care Technology

PITTSBURGH, January 6, 2025 - MolecuLight Inc., a pioneering global company specializing in medical devices for imaging bacterial loads in wounds, has successfully obtained a substantial investment of $27.5 million from Hayfin Capital Management LLP. This strategic funding will propel MolecuLight’s mission to enhance wound treatment methodologies, expanding its reach across various healthcare settings in the United States, Canada, and Europe.

The infusion of capital is set to facilitate the growth of MolecuLight's unique fluorescence imaging technology, designed to assist healthcare providers in detecting and managing infections in real time. The company’s innovative approach enables clinicians to visualize harmful bacteria within wounds, ultimately leading to more informed decision-making and improved patient outcomes.

MolecuLight’s device is already making waves by reducing healing times, minimizing unnecessary antibiotic use, and preventing complications which often lead to costly and extended healthcare interventions. The investment from Hayfin not only reinforces confidence in MolecuLight's technology, but it also aligns perfectly with Hayfin’s strategy to support companies focused on advancing wound care solutions.

CEO Anil Amlani expressed enthusiasm about the partnership, emphasizing that this collaboration will accelerate their goals of improving wound care treatments globally. "Hayfin is a leader in alternative investment management and has a proven track record in the wound care sector. With their support, we aim to broaden our reach to more healthcare professionals and patients while advancing our technology," said Amlani.

In addition to their immediate growth plans, MolecuLight is focused on developing advanced features for its imaging systems, including thermal imaging capabilities and 3D wound visualization tools. These enhancements are expected to be unveiled in the coming months, showcasing the company’s commitment to innovation in healthcare.

Andrew Merrill, managing director at Hayfin, noted, "We are excited to partner with MolecuLight. Their imaging device stands out in the marketplace and addresses a significant gap in the wound care industry, transforming how patients are treated. This funding will bolster MolecuLight’s growth efforts while further benefiting the healthcare system as a whole."

Healthcare providers are increasingly acknowledging the advantages of real-time bacterial detection and imaging technology. The integration of such systems into clinical workflows is becoming essential in modern healthcare, enhancing the efficiency of treatment plans tailored to individual patient needs.

MolecuLight is recognized as a leader in point-of-care fluorescence imaging, with its FDA-approved diagnostic device now available to healthcare professionals. The company is dedicated to empowering clinicians with tools that improve diagnostic precision and expedite healing. By addressing bacterial infections with timely and accurate imaging, MolecuLight's technology promotes a more effective treatment approach tailored to the unique situations of patients.

As MolecuLight continues its trajectory of innovation and expansion, the healthcare community eagerly anticipates the impact of this investment on global wound care practices. The expected advancements will not only improve clinical outcomes for patients but also contribute to overall healthcare efficiency by minimizing complications and optimizing treatment strategies. The future looks promising for MolecuLight as it steers the evolution of wound care technology, backed by strong partners like Hayfin.

About MolecuLight

MolecuLight is at the forefront of developing fluorescence imaging solutions that revolutionize wound management. By offering the only FDA-cleared device capable of detecting elevated bacterial loads, MolecuLight empowers healthcare providers to make timely and informed treatment decisions. For more information, visit MolecuLight's website.

About Hayfin

Hayfin Capital Management is a prominent alternative asset management firm with approximately €32 billion in assets under management. They provide investors with attractive risk-adjusted returns through private debt, liquid credit, and private equity solutions. More information can be found at Hayfin's website.